EUVIMEDEUVIMED entdecken
Crossref

Non‐alcoholic fatty liver disease increases the risk of biochemical recurrence in high‐grade metastatic prostate cancer patients

Hongyi Zhang, Wenbo Yang, Bin Zhang, Jiahui Wu, Wei Zhang, Zhenlong Wang, Jie Cui

Asia-Pacific Journal of Clinical Oncology · 2024-12 · 20 (6) · 707-713

DOI: 10.1111/ajco.14094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 05.07.2024. Verfasst von Hongyi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Non-alcoholic Fatty Liver Disease, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Science and Technology Department of Shaanxi Province, Education Department of Shaanxi Province, Xi'an Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non‐alcoholic fatty liver disease (NAFLD) has been reported to be helpful to identify high‐risk individuals of developing prostate cancer. Our aim is to investigate the relationship between NAFLD and biochemical recurrence in metastatic prostate cancer patients.

Methods

We retrospectively investigated 602 patients with metastatic prostate cancer receiving the androgen deprivation therapy. Liver fat was estimated with liver‐to‐spleen ratio by computed tomography (CT) scans. The relationship between NAFLD and biochemical recurrence was investigated with Cox models. The model for biochemical recurrence was adjusted for multiple variables.

Results

NAFLD was significantly associated with biochemical recurrence in patients with Gleason score ≥4+3 when adjusting for each of body mass index (hazards ratio [HR] = 1.38; 95% confidence interval [CI] = 1.08–1.77; p = 0.01), visceral adipose tissue (HR = 1.36; 95% CI = 1.07–1.74; p = 0.01), hypertension (HR = 1.41; 95% CI = 1.10–1.80; p = 0.01), and diabetes mellitus (HR = 1.42; 95% CI = 1.11–1.82; p = 0.01), using age and prostate‐specific antigen level as potential confounder. The 2‐year biochemical recurrence rate in the Gleason score ≥4+3 patients with and without NAFLD was 84.0% (100/119) and 72.2% (130/180), respectively ( p = 0.018). The median biochemical recurrence free survival of the Gleason score ≥4+3 patients with and without NAFLD were 17 and 21 months, respectively ( p = 0.005).

Conclusions

NAFLD is an independent risk factor for biochemical recurrence in patients with high‐grade metastatic prostate cancer. If validated in prospective studies, future research should test whether treatment of NAFLD can lead to better prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNon-alcoholic Fatty Liver DiseaseNeoplasm Recurrence, LocalHumansMaleRetrospective StudiesAgedMiddle AgedRisk FactorsNeoplasm GradingProstate-Specific Antigen

Stichwörter der Autor:innen

androgen deprivation therapybiochemical recurrencemetastatic prostate cancernon‐alcoholic fatty liver disease

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
  • Department of Oncology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
  • Department of Urology, The Second Affiliated Hospital, Air Forth Medical University, Xi'an, Shaanxi, China.
  • Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Department of General Practice, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.

Förderung

  • Science and Technology Department of Shaanxi Province
  • Education Department of Shaanxi Province
  • Xi'an Science and Technology Program

Zitieren

APA

Zhang, H., Yang, W., Zhang, B., Wu, J., Zhang, W., Wang, Z., & Cui, J. (2024). Non‐alcoholic fatty liver disease increases the risk of biochemical recurrence in high‐grade metastatic prostate cancer patients. Asia-Pacific Journal of Clinical Oncology, 20(6), 707-713. https://doi.org/10.1111/ajco.14094

Vancouver

Zhang H, Yang W, Zhang B, Wu J, Zhang W, Wang Z, et al. Non‐alcoholic fatty liver disease increases the risk of biochemical recurrence in high‐grade metastatic prostate cancer patients. Asia-Pacific Journal of Clinical Oncology. 2024;20(6):707-713. doi:10.1111/ajco.14094

BibTeX
@article{Zhang2024,
  author = {Zhang, Hongyi and Yang, Wenbo and Zhang, Bin and Wu, Jiahui and Zhang, Wei and Wang, Zhenlong and Cui, Jie},
  title = {Non‐alcoholic fatty liver disease increases the risk of biochemical recurrence in high‐grade metastatic prostate cancer patients},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2024},
  volume = {20},
  number = {6},
  pages = {707--713},
  doi = {10.1111/ajco.14094}
}
Kostenlos starten →